EUCTR2020-000557-27-PL进行中（未招募）1 期
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) - TRANSFORM-2
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject = 18 years of age.
- •Subject must be able to complete the MFSAF v4.0 on at least 4 out of 7 days prior to randomisation.
- •- Subject has at least 2 symptoms with a score = 3 or a total score of = 12, as measured by the MFSAF v4.0.
- •Subject with a documented diagnosis of primary MF, post polycythemia vera (PPV)-MF, or post essential thrombocythemia (PET)–MF as defined by the World Health Organization classification.
- •Subject classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).
- •Subject must currently be on treatment or have received prior treatment with a single JAK2 inhibitor, ruxolitinib, and meet one of the following criteria (in addition to the minimum splenomegaly and symptom burden also required for eligibility):
- •- Prior treatment with ruxolitinib for = 24 weeks that was stopped due to lack of spleen response, or loss of spleen response or symptom control after a previous response, or was continued despite relapsed/refractory status.
- •- Prior treatment with ruxolitinib for < 24 weeks with documented disease progression while on JAK2 inhibitor therapy.
- •Subject has splenomegaly defined as palpable spleen measurement = 5 cm below costal margin or spleen volume = 450 cm^3 as assessed centrally by MRI or CT scan.
- •Subject has a baseline platelet count = 100 × 10^9 /L.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 285
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Subject must not have received prior treatment with a BH3-mimetic compound, bromodomain and extra-terminal (BET) inhibitor, or prior use of >1 JAK2 inhibitor.
- •Subject must not be eligible for allogeneic stem cell transplantation at the time of study entry, due to age, comorbidities, or unfit for unrelated or unmatched donor transplant.
- •Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
- •Subject must not receive medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period.
- •Subject must not receive anticancer therapy including chemotherapy, radiation therapy, hormonal therapy within 30 days prior to first dose of study drug, and during the study treatment period (other than any overlapping therapy as part of the selected BAT)
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, phase 3 study studying the efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in patients relapsed myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000557-27-SEAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
1 期
A randomized, open-label, phase 3 study studying the efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in patients relapsed myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000557-27-GBAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
1 期
A randomized, open-label, phase 3 study studying the efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in patients relapsed myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000557-27-HRAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
1 期
A randomized, open-label, phase 3 study studying the efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in patients relapsed myelofibrosisMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000557-27-ITABBVIE DEUTSCHLAND GMBH & CO. KG330
进行中（未招募）
1 期
A randomized, open-label, phase 3 study studying the efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in patients relapsed myelofibrosisMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000557-27-HUAbbVie Deutschland GmbH & Co. KG330